Cyclacel Pharmaceuticals, Inc. (CYCC) Tops Q1 EPS by 2c
Tweet Send to a FriendGet Alerts CYCC Hot Sheet
Price: $3.05 -0.65%
Revenue Growth %: -100.0%
Financial Fact:
Research and development: 1.58M
Today's EPS Names:
DSX, REDF, REX, More
Revenue Growth %: -100.0%
Financial Fact:
Research and development: 1.58M
Today's EPS Names:
DSX, REDF, REX, More
Trade CYCC Now!
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q1 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $192 thousand versus the consensus estimate of $180 thousand.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
- Target Corp. (TGT) Misses Q1 Views, Issues Mixed Outlook
- Compuware Corp (CPWR) Reports In-Line Q4 EPS; Guides FY14 EPS, Revs
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
